Supernus Makes a Parkinson’s Play With $300M Deal for US WorldMeds Drugs

Supernus Pharmaceuticals is expanding its central nervous system (CNS) drug lineup through a deal to acquire four US WorldMeds products with applications in Parkinson’s disease.